Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 18, 2016. The document serves as a transaction notification reporting changes in the notional interest of specific Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The transactions relate to the re-investment of dividends paid on October 13, 2016, under the Company's 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing does not contain corporate financial statements, revenue, profit, cash flow, or debt metrics. It exclusively details share transaction volumes and prices for executive compensation plans.
| Instrument | Transaction Price | Total Aggregated Volume |
|---|---|---|
| Ordinary Shares (GBP) | £17.00 | 10,867.06 (Sum of individual PDMR volumes) |
| American Depositary Shares (USD) | $42.39 | 1,889.52 (Sum of individual PDMR volumes) |
Note: The aggregated volumes above are calculated by summing the specific "Aggregated volume" figures listed for each executive in the text.
Material Changes
The filing reports an increase in notional interest for the following executives due to dividend re-investment:
- Sir Andrew Witty (CEO): 3,155.638 Ordinary Shares
- Ms E Walmsley (CEO Designate): 1,224.146 Ordinary Shares
- Mr R G Connor (President, Global Manufacturing & Supply): 697.320 Ordinary Shares
- Mr S Dingemans (CFO): 1,697.968 Ordinary Shares
- Mr N Hirons (SVP, Global Ethics & Compliance): 445.596 Ordinary Shares
- Mr S A Hussain (President, Global Pharmaceuticals): 1,264.948 Ordinary Shares
- Mr D S Redfern (Chief Strategy Officer): 875.454 Ordinary Shares
- Dr M M Slaoui (Chairman, Global Vaccines): 1,220.178 ADSs
- Ms C Thomas (SVP, Human Resources): 1,032.946 Ordinary Shares
- Mr P C Thomson (SVP, Communications & Government Affairs): 374.292 Ordinary Shares
- Mr D E Troy (SVP & General Counsel): 669.344 ADSs
- Dr P J T Vallance (President, Pharmaceuticals R&D): 1,693.318 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. The document is strictly a regulatory disclosure of share plan activity.
Investor Verification Checklist
- Verify the dividend payment date of October 13, 2016, to confirm the timing of the re-investment.
- Confirm the share price of £17.00 for Ordinary Shares and $42.39 for ADSs on the transaction date.
- Note that Ms E Walmsley is listed as "CEO Designate," indicating a leadership transition period.
- Understand that these transactions represent "notional interest" increases within a deferred bonus plan, not open-market purchases or sales.